Prevention of meningococcal serogroup C disease by NeisVac-C™

被引：23

作者：

Borrow, Ray ^{[1
]}

Findlow, Jamie ^{[1
]}

机构：

[1] Manchester Royal Infirm, Vaccine Evaluat Unit, Hlth Protect Agcy NW, Manchester M13 9WZ, Lancs, England

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 03期

关键词：

efficacy; herd immunity; immunogenicity; meningococcal serogroup C conjugate vaccine; NeisVac-C (TM); reactogenicity; TOXOID CONJUGATE VACCINE; B VACCINE; BACTERICIDAL ACTIVITY; IMMUNOLOGICAL MEMORY; UNITED-KINGDOM; HUMAN IMMUNITY; IMMUNOGENICITY; TETANUS; REACTOGENICITY; IMMUNIZATION;

D O I：

10.1586/14760584.8.3.265

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

NeisVac-C (TM) has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.

引用

页码：265 / 279

页数：15

共 59 条

[1] Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
Abeyagunawardena, AS
Goldblatt, D
Andrews, N
Trompeter, RS
[J]. LANCET, 2003, 362 (9382) : 449 - 450
[2] Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
Andrews, N
Borrow, R
Miller, E
[J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) : 780 - 786
[3] Post-licensure safety of the meningococcal group C conjugate vaccine
Andrews, Nick
Stowe, Julia
Miller, Elizabeth
Taylor, Brent
[J]. HUMAN VACCINES, 2007, 3 (02): : 59 - 63
[4] Arnason Sigurdur, 2008, Laeknabladid, V94, P523
[5] Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
Auckland, Cressida
Gray, Stephen
Borrow, Ray
Andrews, Nick
Goldblatt, David
Ramsay, Mary
Miller, Elizabeth
[J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) : 1745 - 1752
[6] Meningococcal surrogates of protection - serum bactericidal antibody activity
Borrow, R
Balmer, P
Miller, E
[J]. VACCINE, 2005, 23 (17-18) : 2222 - 2227
[7] Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom
Borrow, R
Goldblatt, D
Finn, A
Southern, J
Ashton, L
Andrews, N
Lal, G
Riley, C
Rahim, R
Cartwright, K
Allan, G
Miller, E
[J]. INFECTION AND IMMUNITY, 2003, 71 (10) : 5549 - 5555
[8] Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls
Borrow, R
Southern, J
Andrews, N
Peake, N
Rahim, R
Acuna, M
Martin, S
Miller, E
Kaczmarski, E
[J]. VACCINE, 2001, 19 (23-24) : 3043 - 3050
[9] Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection
Borrow, R
Andrews, N
Goldblatt, D
Miller, E
[J]. INFECTION AND IMMUNITY, 2001, 69 (03) : 1568 - 1573
[10] Long-term protection in children with meningococcal C conjugate vaccination: lessons learned
Borrow, Ray
Miller, Elizabeth
[J]. EXPERT REVIEW OF VACCINES, 2006, 5 (06) : 851 - 857

← 1 2 3 4 5 6 →